A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

被引：0
|
作者：
Meng, Xiangrui [1 ]
Shan, Zhengzheng [1 ]
Guan, Lulu [1 ]
Dao, Xin [1 ]
Fan, Qingxia [1 ]
Wang, Feng [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-5651-9270-10662; 298-145-222-184-1022-9124; 261-566-9718-9794; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 3282-3306-4614-3827; 3; 2; 2461; 3216; 1704; 239; 6; 1; 38092-34311; 38092-21759; 38116-38094-8; 38092-20072;
D O I：
10.1200/JCO.2024.42.3_suppl.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：335 / 335
页数：1
相关论文
共 50 条
  • [21] First-line (1L) treatment patterns in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (GC/GEJC/EAC): Data from the Spanish AGAMENON-SEOM registry
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    Gallego Plazas, J.
    Custodio, A.
    Visa, L.
    Martinez de Castro, E.
    Gomez Gonzalez, L.
    Moreno Gutierrez, M.
    Polanco Sanchez, C.
    Xiao, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S258 - S258
  • [22] Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
    Di Lauro, Luigi
    Giacinti, Laura
    Arena, Maria Grazia
    Sergi, Domenico
    Fattoruso, Silvia Ileana
    Giannarelli, Diana
    Lopez, Massimo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2009, 28
  • [23] A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer
    Zhang, Yang
    Wang, Zi-Xian
    Shen, Lin
    Li, Jin
    Huang, Jing
    Su, Wei-Guo
    Zhang, Dong-Sheng
    Xu, Rui-Hua
    CANCER COMMUNICATIONS, 2023, 43 (01) : 150 - 153
  • [24] Efficacy and safety of toripalimab combination with SOX regimen as a first-line treatment in patients with unresectable locally advanced or recurrent/metastatic gastric/gastroesophageal junction cancer: Preliminary data from a single-armed, exploratory study.
    Lin, Xiaolin
    Xia, Qing
    Han, Ting
    Zhuo, Meng
    Yang, Haiyan
    Qiu, Xiaoxia
    Wang, Liwei
    Xiao, Xiuying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
    Babu, K. Govind
    Chaudhuri, Tamojit
    Lakshmaiah, K. C.
    Dasappa, Lokanatha
    Jacob, Linu Abraham
    Babu, M. C. Suresh
    Rudresha, A. H.
    Lokesh, K. N.
    Rajeev, L. K.
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (02) : 85 - 87
  • [26] First-line panitumumab plus docetaxel and cisplatin in advanced gastric or gastroesophageal junction adenocarcinoma: Results of a phase II trial (SPIGA).
    Aldana, Guillermo Alfonso Quintero
    Folgar, Sonia Candamio
    Mendez, Jose Carlos Mendez
    Reboredo, Margarita
    Fernandez, Monica Jorge
    Constenla, Manuel
    Reinoso, Carlos Romero
    Fernandez, Mercedes Salgado
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
    Lee, K-W.
    Bai, L-Y.
    Jung, M.
    Ying, J.
    Im, Y-H.
    Oh, D-Y.
    Cho, J. Y.
    Oh, S. C.
    Chao, Y.
    Zhou, P.
    Bao, Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S855 - S856
  • [28] A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203)
    Sun, W.
    Powell, M. E.
    O'Dwyer, P.
    Ansari, R. H.
    Benson, A. B., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur Gregory Ang
    Mulder, Karen E.
    Brezden-Masley, Christine
    Vickers, Michael M.
    Monzon, Jose Gerard
    Kennecke, Hagen F.
    Goel, Rakesh
    Ghosh, Sunita
    Marginean, Horia
    Vos, Larissa Joy
    Raynard, SeeSee Juliana
    Young, Kristine Lee
    Fields, Anthony L. A.
    Maroun, Jean Alfred
    Spratlin, Jennifer L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Toripalimab combined with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wanrui
    Li, Xiaofen
    Chang, Chen
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16244 - E16244
12345